Clavien‐Dindo grade ≤ 2 complications8 · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
NBI + WLC TURBT showed no clear difference in minor adverse event (Clavien‐Dindo grade I and II) compared with WLC TURBT (low certainty).
1 finding from 1 review
Minor complications (3 to 6 weeks · bladder cancer in adults
It is very uncertain whether robotic‐assisted laparoscopic changes minor postoperative complications compared with open radical cystectomy (very low certainty).
1 finding from 1 review
Minor adverse events · people undergoing cystoscopy
Antimicrobial showed no clear difference in minor adverse events compared with placebo or no antibiotics (low certainty).
1 finding from 1 review
Minor adverse events
Desmopressin showed no clear difference in minor adverse events compared with placebo (low certainty).
2 findings from 1 review
Minor adverse events ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events
It is very uncertain whether desmopressin changes minor adverse events compared with alpha‐blocker (very low certainty).
1 finding from 1 review
Minor adverse events
It is very uncertain whether desmopressin plus alpha‐blocker changes minor adverse events compared with alpha‐blocker (very low certainty).
1 finding from 1 review
Minor adverse events
Desmopressin plus alpha‐blocker may leads to lower minor adverse events compared with alpha‐blocker plus anticholinergic (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 19 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in overall survival (OS) ‐ Network (subnet 1) included 19 pairwise… (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 5 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
Adverse events (grade 3 to 4) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time to initiation of first subsequent therapy · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
MSKCC risk group · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 3 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
Serious adverse events (SAEs) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 7 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
IMDC risk groups · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (QoL) We reported this outcome narratively in this review. Here, long‐term results (i.e., at the end of treatment) are presented. In the comparison PAZ versus SUN, QoL was measured using FACIT‐F (score range 0‐52; higher scores rep... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found